News Release
December 03, 2004
Forum Alert: Aethlon Medical Presentation at Informed Investors Biotechnology & Healthcare Stocks Forum at the Crowne Plaza in Foster City on Tuesday, Dec. 7, 2004, 10:00 am PT
/24-7PressRelease.com/ - SAN DIEGO - Dec. 03, 2004 - Aethlon Medical (OTCBB: AEMD) will present at the following forum:
What: Informed Investors Biotechnology & Healthcare Stocks Forum
When: December 7, 2004 @ 10 AM Pacific Time
Where: The Crowne Plaza, 1221 Chess Dr., Foster City, CA 94404
How: To attend live event, pre-registration is necessary. To
register contact Cary Loeser, cloeser@wilink.com,
804-327-3407 or call Customer Service at 888-301-6618
Contact: James Joyce, Chief Executive Officer, jj@aethlonmedical.com
If you are unable to attend the live event, the forum will be available via webcast at http://www.informedinvestors.com/CustomEvent/85135/index.asp?ForumID= 85135. (Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field.)
Aethlon Medical is pioneering the development of viral filtration devices that rapidly reduce the presence of infectious disease and toxins in the body. Aethlon has published compelling human blood studies of the HemopurifierTM to treat HIV/AIDS and Hepatitis-C (HCV), and most recently, has announced that it is developing pathogen filtration devices to treat infectious agents used in biological warfare and terrorism. The Hemopurifier is a proprietary platform technology that converges the established scientific principles of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur. On March 4, 2004, Aethlon announced a cooperative agreement with the National Center for Biodefense (NCBD) at George Mason University. Under the agreement, Aethlon and the NCBD will collaborate to develop pathogen and toxin filtration devices designed to protect the lives of U.S. Military personnel exposed to infectious agents as a result of biological warfare. For additional information, visit the company's Web site at http://www.AethlonMedical.com.
FORUM CONTACT: Cary Loeser, Informed Investors, 804-327-3407, cloeser@wilink.com
Web site: http://www.informedinvestors.com
SOURCE: Aethlon Medical, Inc.
Aethlon Medical, Inc. is a featured Company on http://www.HomelandDefenseStocks.com and http://www.investorideas.com/Research/Industries/Biotech.asp
For full details, click here: http://www.investorideas.com/Companies/AethlonMedical/NewsReleases.asp
Contact:
WILink
Cary Loeser, 804-327-3407
cloeser@wilink.com
Aethlon Medical is pioneering the development of viral filtration devices that rapidly reduce the presence of infectious disease and toxins in the body. Aethlon has published compelling human blood studies of the HemopurifierTM to treat HIV/AIDS and Hepatitis-C (HCV), and most recently, has announced that it is developing pathogen filtration devices to treat infectious agents used in biological warfare and terrorism.
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com# # #
Read more Press Releases from Dawn Van Zant:
